Chirfi Guindo Net Worth

The estimated Net Worth of Chirfi Guindo is at least $17.6 Million dollars as of 5 August 2024. Mr. Guindo owns over 36,901 units of Biogen Inc stock worth over $11,503,619 and over the last 7 years he sold BIIB stock worth over $1,358,280. In addition, he makes $4,694,520 as Executive Vice President, Head of Global Marketing, and Market Access and Customer Innovation at Biogen Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Guindo BIIB stock SEC Form 4 insiders trading

Chirfi has made over 10 trades of the Biogen Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 36,901 units of BIIB stock worth $4,250,995 on 5 August 2024.

The largest trade he's ever made was exercising 36,901 units of Biogen Inc stock on 5 August 2024 worth over $4,250,995. On average, Chirfi trades about 4,885 units every 115 days since 2017. As of 5 August 2024 he still owns at least 57,781 units of Biogen Inc stock.

You can see the complete history of Mr. Guindo stock trades at the bottom of the page.

Chirfi Guindo biography

Chirfi Guindo has served as an Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation of Biogen Inc. Prior to joining Biogen, Mr. Guindo has spent 27 years in the global pharmaceutical industry and has held several leadership positions at Merck, a pharmaceutical company, in Canada, the U.S., France, Africa and the Netherlands. He worked in several disciplines including Finance, Sales & Marketing, General Management and Global Strategy/Product Development in specialty, acute and hospital care. Most recently Mr. Guindo was Vice President and Managing Director and President and Managing Director of Merck Canada from October 2014 to November 2017. From January 2011 to October 2014, he was Vice President and General Manager, Global HIV Franchise at Merck.

What is the salary of Chirfi Guindo?

As the Executive Vice President, Head of Global Marketing, and Market Access and Customer Innovation of Biogen Inc, the total compensation of Chirfi Guindo at Biogen Inc is $4,694,520. There are 3 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.

How old is Chirfi Guindo?

Chirfi Guindo is 53, he's been the Executive Vice President, Head of Global Marketing, and Market Access and Customer Innovation of Biogen Inc since 2017. There are 19 older and 4 younger executives at Biogen Inc. The oldest executive at Biogen Inc is Stelios Papadopoulos, 72, who is the Independent Chairman of the Board.

What's Chirfi Guindo's mailing address?

Chirfi's mailing address filed with the SEC is MERCK & CO., INC., 126 EAST LINCOLN AVENUE, RAHWAY, NJ, 07065.

Insiders trading at Biogen Inc

Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner, and Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.

What does Biogen Inc do?

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili

Complete history of Mr. Guindo stock trades at Biogen Inc and Merck & Co Inc

Biogen Inc executives and stock owners

Biogen Inc executives and other stock owners filed with the SEC include:

• Michel Vounatsos,
  Chief Executive Officer, Director
• Susan Alexander,
  Executive Vice President, Chief Legal Officer and Secretary
• Alfred Sandrock,
  Executive Vice President, Research and Development, Chief Medical Officer
• Chirfi Guindo,
  Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
• Michel Vounatsos,
  CEO & Director
• Susan H. Alexander Esq.,
  Exec. VP, Chief Legal Officer & Sec.
• Susan H. Alexander,
  Exec. VP, Chief Legal Officer & Sec.
• Michael R. McDonnell,
  Exec. VP & CFO
• Chirfi Guindo,
  Exec. VP of Global Product Strategy & Commercialization
• Stelios Papadopoulos,
  Independent Chairman of the Board
• Robert Pangia,
  Independent Director
• Brian Posner,
  Independent Director
• Alexander Denner,
  Independent Director
• Nancy Leaming,
  Independent Director
• Caroline Dorsa,
  Independent Director
• Stephen Sherwin,
  Independent Director
• Eric Rowinsky,
  Independent Director
• Richard Mulligan,
  Independent Director
• Jesus Mantas,
  Independent Director
• William Hawkins,
  Independent Director
• Robin Kramer,
  Chief Accounting Officer, Vice President
• Daniel Karp,
  Executive Vice President, Corporate Development
• Alphonse Galdes,
  Executive Vice President, Pharmaceutical Operations and Technology
• Ginger Gregory,
  Chief Human Resource Officer, Executive Vice President
• Michael McDonnell,
  Chief Financial Officer, Executive Vice President
• Dr. Sanjay Jariwala,
  Sr. VP of Worldwide Medical
• Nicole Murphy,
  Head of Pharmaceutical Operations & Technology
• Dr. Anabella Villalobos Ph.D.,
  Sr. VP of Biotherapeutic & Medicinal Sciences
• Dr. Alphonse Galdes,
  Exec. VP of Pharmaceutical Operations & Technology
• Dr. Ginger Gregory,
  Exec. VP & Chief HR Officer
• Natacha Gassenbach,
  Chief Communication Officer & Head of Corp. Affairs
• Michael Hencke,
  Director of Investor Relations
• Mark J. Hernon,
  Sr. VP & Chief Information Officer
• Robin C. Kramer,
  Sr. VP & Chief Accounting Officer
• George A Scangos,
  Chief Executive Officer
• Adriana Karaboutis,
  EVP, Tech. and Bus. Solutions
• Michael D Ehlers,
  EVP, Research and Development
• Gregory F Covino,
  VP, Chief Accounting Officer
• Lynn Schenk,
  Director
• Paul Mc Kenzie,
  EVP Pharmaceutical Oper & Tech
• Paul J Clancy,
  CFO
• Kenneth Di Pietro,
  EVP Human Resources
• Adam Koppel,
  SVP, Chief Strategy Officer
• Susan Langer,
  Director
• Jean Paul Kress,
  EVP Pres Int'l & Global Hd GTO
• Priya Singhal,
  Head of Development
• Jeffrey D Capello,
  EVP & Chief Financial Officer
• Monish D Patolawala,
  Director
• Phillip A Sharp,
  Director
• Steven H Holtzman,
  EVP Corp Devel and Strategy
• John Cox,
  EVP Pharmaceutical Oper & Tech
• Spyridon Artavanis Tsakonas,
  SVP, Chief Scientific Officer
• William Young,
  Director
• Raymond Pawlicki,
  SVP, Chief Information Officer
• Stuart A Kingsley,
  EVP, Global Comm. Operations
• Douglas E Williams,
  EVP Research & Development
• Craig Eric Schneier,
  EVP, Human Resources
• Robert E. Gagnon,
  Chief Acct Officer VP & Contr
• Francesco Granata,
  EVP Global Commercial Operatio
• James C Mullen,
  CEO and President
• Michael F Mac Lean,
  SVP, Chief Accounting Officer
• Bruce Ross,
  Director
• Robert A Hamm,
  SVP, Immunology Business Unit
• Cecil B Pickett,
  President, R & D
• Marijn E Dekkers,
  Director
• Lawrence C Best,
  Director
• Faheem Hasnain,
  SVP, Oncology SBU
• Hans Peter Hasler,
  SVP, International
• Mark C Wiggins,
  EVP - Business Development
• Michael Lytton,
  EVP Corporate & Business Devel
• Alan Glassberg,
  Director
• John Michael Dunn,
  EVP - New Ventures
• Michael Gilman,
  EVP - Research
• Thomas J Bucknum,
  EVP. General Counsel, Sec.
• Nabil Hanna,
  EVP, Research
• William H Rastetter,
  Executive Chairman
• William R Rohn,
  Exec VP & COO
• Sylvie L Gregoire,
  EVP, Bus. Dev & Program Mgmt.
• Burt A Adelman,
  EVP, Development
• Alan Belzer,
  Director
• Michael Kowolenko,
  SVP, Pharm Ops & Technology
• Peter N Kellogg,
  Executive Vice President, CFO
• Mary L Good,
  Director
• Thomas F Keller,
  Director
• Connie Matsui,
  Sr V P, Planning& Resource Dev
• Christopher Viehbacher,
  President and CEO
• Maria C Freire,
  Director
• William D /Ca/ Jones,
  Director
• Nicole Murphy,
  Head of Pharm Ops and Tech
• Rachid Izzar,
  Head of Global Product Strat.
• Adam Keeney,
  Head of Corporate Development
• Jane Grogan,
  Head of Research